Cargando…

Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease

We report a patient with connective tissue disease who developed modest severe acute respiratory syndrome coronavirus 2 receptor binding domain–specific antibody levels and a lack of neutralization capacity, despite having received 3 mRNA coronavirus disease 2019 vaccines and holding anti-B-cell the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peluso, Michael J, Munter, Sadie E, Lynch, Kara L, Yun, Cassandra, Torres, Leonel, Iyer, Nikita S, Donatelli, Joanna, Ryan, Lindsay, Deitchman, Amelia N, Deeks, Steven G, Rutishauser, Rachel L, Henrich, Timothy J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344490/ https://www.ncbi.nlm.nih.gov/pubmed/34395717 http://dx.doi.org/10.1093/ofid/ofab393

Ejemplares similares

Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations
por: Sun, Bing, et al.
Publicado: (2021)

The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms
por: Buck, Amanda M., et al.
Publicado: (2023)

First-in-human immunoPET imaging of HIV-1 infection using (89)Zr-labeled VRC01 broadly neutralizing antibody
por: Beckford-Vera, Denis R., et al.
Publicado: (2022)

Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19
por: Peluso, Michael J., et al.
Publicado: (2021)

Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms
por: Peluso, Michael J., et al.
Publicado: (2021)

LB8. Lower SARS-CoV-2 IgG and Pseudovirus Neutralization Titers Post-mRNA Vaccination among People Living with HIV
por: Spinelli, Matthew A, et al.
Publicado: (2021)

Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study
por: Spinelli, Matthew A, et al.
Publicado: (2021)

SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay
por: Peluso, Michael J., et al.
Publicado: (2021)

SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study
por: Spinelli, Matthew A, et al.
Publicado: (2021)

Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection
por: Reynolds, Catherine J., et al.
Publicado: (2020)

Superinfection by Discordant Subtypes of HIV-1 Does Not Enhance the Neutralizing Antibody Response against Autologous Virus
por: Mayr, Luzia M., et al.
Publicado: (2012)

SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay
por: Peluso, Michael J., et al.
Publicado: (2021)

Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
por: Bootz, Anna, et al.
Publicado: (2017)

Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus
por: Mayr, LM, et al.
Publicado: (2012)

Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions
por: Peluso, Michael J., et al.
Publicado: (2022)

Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity
por: Pei, Xiaolei, et al.
Publicado: (2020)

Ricin Antibodies’ Neutralizing Capacity against Different Ricin Isoforms and Cultivars
por: Orsini Delgado, Maria Lucia, et al.
Publicado: (2021)

Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada
por: Costiniuk, Cecilia T., et al.
Publicado: (2023)

Impact of Pre-Existing Chronic Viral Infection and Reactivation on the Development of Long COVID
por: Peluso, Michael J., et al.
Publicado: (2022)

Chronic viral coinfections differentially affect the likelihood of developing long COVID
por: Peluso, Michael J., et al.
Publicado: (2023)

COVID-19 and human milk: SARS-CoV-2, antibodies, and neutralizing capacity
por: Pace, Ryan M., et al.
Publicado: (2020)

Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection
por: Elledge, Susanna K., et al.
Publicado: (2020)

Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System
por: Bhiman, Jinal N., et al.
Publicado: (2017)

Enhancement of toxin- and virus-neutralizing capacity of single-domain antibody fragments by N-glycosylation
por: Harmsen, M. M., et al.
Publicado: (2009)

Titration and neutralizing antibody quantification by focus forming assay for Powassan virus
por: Stone, E. Taylor, et al.
Publicado: (2022)

Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus
por: Howell, Katie A., et al.
Publicado: (2017)

Tackling influenza with broadly neutralizing antibodies
por: Corti, Davide, et al.
Publicado: (2017)

Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies
por: Buck, Amanda M., et al.
Publicado: (2023)

Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway
por: Mielke, Dieter, et al.
Publicado: (2019)

Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals
por: Molinos-Albert, Luis M, et al.
Publicado: (2014)

Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community
por: Appa, Ayesha, et al.
Publicado: (2020)

ROLE OF ANTIBODIES, INFLAMMATORY MARKERS, AND ECHOCARDIOGRAPHIC FINDINGS IN POST-ACUTE CARDIOPULMONARY SYMPTOMS AFTER SARS-COV-2 INFECTION
por: Durstenfeld, Matthew, et al.
Publicado: (2022)

Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
por: Landais, Elise, et al.
Publicado: (2018)

NEUTRALIZING ANTIBODIES IN ABORTIVE POLIOMYELITIS
por: Trask, James D., et al.
Publicado: (1933)

Neutralizing antibodies in convalescent patients
por: Uhl, Lion F. K., et al.
Publicado: (2020)

Neutralizing antiviral antibody responses
por: Zinkernagel, Rolf M., et al.
Publicado: (2001)

Hexamerization of Anti-SARS CoV IgG1 Antibodies Improves Neutralization Capacity
por: Pande, Kalyan, et al.
Publicado: (2022)

Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle
por: El Amrani, Mohsin, et al.
Publicado: (2019)

Discordant antibody and cellular responses to Pneumocystis major surface glycoprotein variants in mice
por: Bishop, Lisa R, et al.
Publicado: (2012)

Universal Polymerase Chain Reaction and Antibody Testing Demonstrate Little to No Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in a Rural Community
por: Appa, Ayesha, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oqc90f0vu9o90qru9lnkel9v95